CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	EGFR	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Mok et al., 2009
B	NRAS	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Binimetinib	Dummer et al., 2017
A	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Khozin et al., 2014
A	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Khozin et al., 2014
A	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Dungo et al., 2013
A	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Dungo et al., 2013
A	KRAS	Mutation	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Selumetinib,Docetaxel	Jänne et al., 2017
B	TP53	Mutation	Prognostic	Supports		Lung Non-small Cell Carcinoma		Shepherd et al., 2017
B	BRAF	Non-V600	Prognostic	Supports	Better Outcome	Colorectal Cancer		Jones et al., 2017
B	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Alectinib,Crizotinib	Peters et al., 2017
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Dacomitinib	Ramalingam et al., 2016
A	KRAS	Mutation	Predictive	Supports	Resistance	Colorectal Cancer	Panitumumab,Cetuximab	Benson et al., 2017
D	MYC	Overexpression	Predictive	Supports	Sensitivity/Response	Multiple Myeloma	JQ-1	Delmore et al., 2011
B	BRCA1	Loss-of-function	Predictive	Supports	Sensitivity/Response	Her2-receptor Negative Breast Cancer	Olaparib	Robson et al., 2017
B	PLCG2	MUTATION	Prognostic	Supports	Poor Outcome	Chronic Lymphocytic Leukemia		Woyach et al., 2014
B	MET	Overexpression	Predictive	Does Not Support	Sensitivity/Response	Stomach Carcinoma	Rilotumumab	Catenacci et al., 2017
A	FOXL2	C134W	Diagnostic	Supports	Positive	Ovarian Sex-cord Stromal Tumor		Goulvent et al., 2016
A	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib,Cobimetinib	Ascierto et al., 2016
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib,Trametinib	Long et al., 2017
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Dabrafenib	Long et al., 2017
D	ABL1	R351W	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Imatinib	Testoni et al., 2016
A	CALR	Mutation	Diagnostic	Supports	Positive	Essential Thrombocythemia		Arber et al., 2016
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Dabrafenib	Long et al., 2014
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib,Trametinib	Long et al., 2014
B	KIAA1549::BRAF	Fusion	Diagnostic	Supports	Positive	Pilocytic Astrocytoma		Jones et al., 2013
B	IGH::CRLF2	Fusion	Prognostic	Supports	Poor Outcome	Childhood B-cell Acute Lymphoblastic Leukemia		Harvey et al., 2010
A	BRCA1	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Olaparib	Moore et al., 2018
A	BRCA2	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Olaparib	Moore et al., 2018
A	v::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Shaw et al., 2019
A	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Alectinib	Peters et al., 2017
A	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Ceritinib	Shaw et al., 2017
A	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Encorafenib,Binimetinib	Dummer et al., 2018
A	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Breast Cancer	Alpelisib,Fulvestrant	André et al., 2019
A	PIK3CA	Q546E OR PIK3CA Q546R	Predictive	Supports	Sensitivity/Response	Breast Cancer	Alpelisib,Fulvestrant	André et al., 2019
A	PIK3CA	H1047R OR PIK3CA H1047Y OR PIK3CA H1047L	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Alpelisib	André et al., 2019
A	IKZF1	Deletion	Prognostic	Supports	Poor Outcome	B-lymphoblastic Leukemia/lymphoma		Yeoh et al., 2018
D	FLT3	ITD	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Ponatinib	Gozgit et al., 2011
A	BRCA1	Loss-of-function	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	Olaparib	Golan et al., 2019
A	BRCA2	Loss-of-function	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	Olaparib	Golan et al., 2019
A	IKZF1	Deletion	Prognostic	Supports	Poor Outcome	B-lymphoblastic Leukemia/lymphoma		Jia et al., 2014
D	KIT	T670I	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Garner et al., 2014
D	KIT	T670I	Predictive	Does Not Support	Resistance	Gastrointestinal Stromal Tumor	Ponatinib,Sunitinib	Garner et al., 2014
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Encorafenib,Binimetinib,Cetuximab	Kopetz et al., 2019
A	FLT3	ITD OR FLT3 D835 OR FLT3 I836	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Gilteritinib	Perl et al., 2019
D	PRPS1	S103T	Predictive	Supports	Resistance	B-lymphoblastic Leukemia/lymphoma	Thioguanine,Mercaptopurine	Li et al., 2015
D	PRPS1	A190T	Predictive	Supports	Resistance	B-lymphoblastic Leukemia/lymphoma	Thioguanine,Mercaptopurine	Li et al., 2015
B	TP53	Mutation	Prognostic	Supports	Poor Outcome	Medulloblastoma SHH Activated		Schwalbe et al., 2017
C	GOLGA4::RAF1	Fusion	Predictive	Supports	Sensitivity/Response	Melanoma	Cobimetinib,Trametinib	McEvoy et al., 2019
A	ETV6::RUNX1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With ETV6-RUNX1		Arber et al., 2016
A	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Alectinib	Hida et al., 2017

Page 3 of 96

Previous Next